Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Respir Res ; 21(1): 59, 2020 Feb 21.
Article in English | MEDLINE | ID: mdl-32085773

ABSTRACT

BACKGROUND: Bronchopulmonary dysplasia continues to cause important respiratory morbidity throughout life, and new therapies are needed. The common denominator of all BPD cases is preterm birth, however most preclinical research in this area focusses on the effect of hyperoxia or mechanical ventilation. In this study we investigated if and how prematurity affects lung structure and function in neonatal rabbits. METHODS: Pups were delivered on either day 28 or day 31. For each gestational age a group of pups was harvested immediately after birth for lung morphometry and surfactant protein B and C quantification. All other pups were hand raised and harvested on day 4 for the term pups and day 7 for the preterm pups (same corrected age) for lung morphometry, lung function testing and qPCR. A subset of pups underwent microCT and dark field imaging on day 0, 2 and 4 for terms and on day 0, 3, 5 and 7 for preterms. RESULTS: Preterm pups assessed at birth depicted a more rudimentary lung structure (larger alveoli and thicker septations) and a lower expression of surfactant proteins in comparison to term pups. MicroCT and dark field imaging revealed delayed lung aeration in preterm pups, in comparison to term pups. Preterm birth led to smaller pups, with smaller lungs with a lower alveolar surface area on day 7/day 4. Furthermore, preterm birth affected lung function with increased tissue damping, tissue elastance and resistance and decreased dynamic compliance. Expression of vascular endothelial growth factor (VEGFA) was significantly decreased in preterm pups, however in the absence of structural vascular differences. CONCLUSIONS: Preterm birth affects lung structure and function at birth, but also has persistent effects on the developing lung. This supports the use of a preterm animal model, such as the preterm rabbit, for preclinical research on BPD. Future research that focuses on the identification of pathways that are involved in in-utero lung development and disrupted by pre-term birth, could lead to novel therapeutic strategies for BPD.


Subject(s)
Lung/growth & development , Lung/pathology , Models, Animal , Premature Birth/pathology , Animals , Animals, Newborn , Female , Lung/metabolism , Male , Pregnancy , Premature Birth/metabolism , Pulmonary Surfactant-Associated Proteins/metabolism , Rabbits , Respiratory Function Tests/methods , Tidal Volume/physiology
2.
Am J Physiol Lung Cell Mol Physiol ; 316(4): L589-L597, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30675804

ABSTRACT

Recent clinical trials in newborns have successfully used surfactant as a drug carrier for an active compound, to minimize systemic exposure. To investigate the translational potential of surfactant-compound mixtures and other local therapeutics, a relevant animal model is required in which intratracheal administration for maximal local deposition is technically possible and well tolerated. Preterm rabbit pups (born at 28 days of gestation) were exposed to either hyperoxia or normoxia and randomized to receive daily intratracheal surfactant, daily intratracheal saline, or no injections for 7 days. At day 7, the overall lung function and morphology were assessed. Efficacy in terms of distribution was assessed by micro-PET-CT on both day 0 and day 7. Lung function as well as parenchymal and vascular structure were altered by hyperoxia, thereby reproducing a phenotype reminiscent of bronchopulmonary dysplasia (BPD). Neither intratracheal surfactant nor saline affected the survival or the hyperoxia-induced BPD phenotype of the pups. Using PET-CT, we demonstrate that 82.5% of the injected radioactive tracer goes and remains in the lungs, with a decrease of only 4% after 150 min. Surfactant and saline can safely and effectively be administered in spontaneously breathing preterm rabbits. The described model and method enable researchers to evaluate intratracheal pharmacological interventions for the treatment of BPD.


Subject(s)
Bronchopulmonary Dysplasia/drug therapy , Drug Delivery Systems , Pulmonary Surfactants/administration & dosage , Animals , Animals, Newborn , Bronchopulmonary Dysplasia/diagnostic imaging , Bronchopulmonary Dysplasia/physiopathology , Disease Models, Animal , Feasibility Studies , Female , Humans , Infant, Newborn , Injections , Lung/diagnostic imaging , Lung/drug effects , Lung/physiopathology , Positron Emission Tomography Computed Tomography , Pregnancy , Premature Birth , Pulmonary Surfactants/pharmacokinetics , Rabbits , Trachea , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...